The vascular marker soluble fms-like tyrosine kinase 1 is associated with disease severity and adverse outcomes in chronic heart failure.
about
Heart failure with recovered ejection fraction: clinical description, biomarkers, and outcomesBiomarker predictors of cardiac hospitalization in chronic heart failure: a recurrent event analysisCalibrated integrated backscatter and myocardial fibrosis in patients undergoing cardiac surgeryMultiple biomarkers for risk prediction in chronic heart failure.Relationship of promising methods in the detection of anthracycline-induced cardiotoxicity in breast cancer patientsPlacental Growth Factor as a Predictor of Cardiovascular Events in Patients with CKD from the NARA-CKD Study.Elevated Soluble Fms-Like Tyrosine Kinase-1 and Placental-Like Growth Factor Levels Are Associated With Development and Mortality Risk in Heart Failure.Circulating multimarker profile of patients with symptomatic heart failure supports enhanced fibrotic degradation and decreased angiogenesis.Plasma levels of hepatocyte growth factor and placental growth factor predict mortality in a general population: a prospective cohort study.Improving prediction of cardiovascular complications of cancer therapy: what does the future hold?Prospective Evaluation of Sunitinib-Induced Cardiotoxicity in Patients with Metastatic Renal Cell Carcinoma.Angiogenic Factors and Risks of Technique Failure and Cardiovascular Events in Patients Receiving Peritoneal Dialysis.Panel of emerging cardiac biomarkers contributes for prognosis rather than diagnosis in chronic heart failure.Sflt-1 in heart failure: relation with disease severity and biomarkers.Prognostic use of soluble fms-like tyrosine kinase-1 and placental growth factor in patients with coronary artery disease.Assessment of late anthracycline-induced cardiotoxicity by 123I-mIBG cardiac scintigraphy in patients treated during childhood and adolescence.Soluble Flt-1 links microvascular disease with heart failure in CKD.Ratio between fms-like tyrosine kinase 1 and placental growth factor in children with congenital heart disease.Soluble Flt-1 release response to heparin use: implications for dialysis patients?Heparin use during dialysis sessions induces an increase in the antiangiogenic factor soluble Flt1.Novel concept to guide systolic heart failure medication by repeated biomarker testing-results from TIME-CHF in context of predictive, preventive, and personalized medicine.Novel biochemical predictors of unfavorable prognosis for stable coronary disease
P2860
Q33740885-778EA29D-3CA8-4FB4-AC27-94883BDF3CCEQ34080388-8B61B2C2-14B5-4E68-AEBC-C11827DB61DAQ36012175-977981DF-D2F0-40D2-9CA2-61CE0404E567Q36070049-8398113C-A197-4057-8EFE-691B77BD2E99Q36181301-C96A086B-B773-47E2-9B0B-257F788DD765Q36223290-63F0767D-6B85-40F8-A401-1FB3CD11AC6FQ36407107-8E98C143-C07A-42F7-AB76-22154B7EA6B0Q36753619-6AD4F2AE-7909-4C7A-B2B6-B81F80D9F54FQ38691253-933786C4-A740-48F6-B9FD-89B245AC5D18Q38978030-9C47D5DF-D322-4910-95A9-26C114C8ADA5Q40336236-A3F8C394-5336-4D56-AF2F-EB4BF3FE08DBQ42751149-0D62532F-410B-46CF-ADA2-2979A4528F12Q43411896-34A58296-ACF1-4980-A1B1-1D9DA1104043Q48682358-564B277C-2251-46F9-97AF-36997AE28A64Q52145290-F421EF70-FEDA-4E10-BC7E-145AE4B3B6BCQ52987912-64E4DC68-0458-4914-B3F1-071679DA10E8Q53536660-950F3A83-2E5D-4F09-A8D2-C691649CCFE5Q54310196-7B722373-A6F9-4D27-B2BD-36EDABB91D11Q54374358-15A99983-72B7-4A5A-BC89-E112C7B8D820Q54378242-9FFCC695-0740-4AED-A0B6-835AA840A9C7Q55409538-A1A9CDEE-D54B-4326-B8B0-CACE0AD2C2D6Q58739842-8EBBA6E7-C370-4BB2-8C46-46C7A744D829
P2860
The vascular marker soluble fms-like tyrosine kinase 1 is associated with disease severity and adverse outcomes in chronic heart failure.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
The vascular marker soluble fm ...... omes in chronic heart failure.
@ast
The vascular marker soluble fm ...... omes in chronic heart failure.
@en
type
label
The vascular marker soluble fm ...... omes in chronic heart failure.
@ast
The vascular marker soluble fm ...... omes in chronic heart failure.
@en
prefLabel
The vascular marker soluble fm ...... omes in chronic heart failure.
@ast
The vascular marker soluble fm ...... omes in chronic heart failure.
@en
P2093
P2860
P1476
The vascular marker soluble fm ...... omes in chronic heart failure.
@en
P2093
Benjamin French
Douglas B Sawyer
James C Fang
Nancy K Sweitzer
Thomas P Cappola
Wayne C Levy
P2860
P304
P356
10.1016/J.JACC.2011.03.032
P407
P577
2011-07-01T00:00:00Z